This study will evaluate safety, tolerability, drug levels, molecular effects and
clinical activity of MRTX849 (adagrasib) in combination with BI 1701963 in patients with
advanced solid tumors that have a KRAS G12C mutation.
Additional locations may be listed on ClinicalTrials.gov for NCT04975256.
See trial information on ClinicalTrials.gov for a list of participating sites.
This study will evaluate safety, tolerability, pharmacokinetics, metabolites,
pharmacodynamics and clinical activity of MRTX849 (adagrasib) in combination with BI
1701963 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an
orally available small molecule inhibitor of KRAS G12C and BI 1701963 is a SOS1 pan-KRAS
inhibitor.
Lead OrganizationMirati Therapeutics